Clinical Research
Retatrutide Studies
Peer-reviewed research and clinical trial data behind the RetaPath protocol. All benchmarks in the app are derived from these published sources. Retatrutide cleared a Phase 3 diabetes trial in March 2026 — FDA approval is getting closer.
Retatrutide — Phase 2 Trial (NEJM 2023)
Jastreboff AM, et al. — New England Journal of Medicine · 2023
The landmark Phase 2 RCT across 338 participants showing up to 17.5% body weight reduction over 24 weeks. Evaluated doses from 1mg to 12mg weekly. Foundation of the RetaPath protocol benchmarks.
Triple Agonism: GIP, GLP-1, and Glucagon Receptor Mechanism
Coskun T, et al. — Molecular Metabolism · 2022
Characterizes Retatrutide's triple receptor agonist mechanism (GIP/GLP-1/glucagon), explaining its superior efficacy vs dual agonists like tirzepatide. Key background for understanding how Retatrutide works.
Cardiovascular & Metabolic Effects of Retatrutide
Lincoff AM, et al. — New England Journal of Medicine · 2023
Analysis of cardiovascular safety and metabolic biomarker changes including HbA1c, triglycerides, and blood pressure from the Phase 2 cohort. Relevant for the biomarker tracking in RetaPath.
Retatrutide for Obesity — 48-Week Extension Data
Jastreboff AM, et al. — Obesity (journal) · 2024
Extended follow-up data beyond the original 24-week trial, showing continued weight loss trajectory at higher doses. Provides longer-term efficacy and safety context.
GLP-1 Receptor Agonists: Muscle Mass & Body Composition
Wilding JPH, et al. — Diabetes, Obesity and Metabolism · 2023
Reviews lean mass preservation concerns with GLP-1 class drugs — directly relevant to the bodybuilding and longevity protocol categories in RetaPath.
Retatrutide Clears Phase 3 Diabetes Trial — CNBC, March 2026
Eli Lilly and Company — CNBC · 2026
Eli Lilly announced retatrutide successfully cleared a late-stage Phase 3 clinical trial for Type 2 diabetes, bringing the drug significantly closer to FDA approval. This follows the landmark Phase 2 obesity results and marks a major milestone for the retatrutide pipeline.
Retatrutide Phase 3 Trials — ClinicalTrials.gov
Eli Lilly and Company — ClinicalTrials.gov · 2024–ongoing
Active Phase 3 trials for Retatrutide across obesity, T2D, and MASH indications. Track enrollment status, endpoints, and estimated completion dates.
Links open PubMed, NEJM, or ClinicalTrials.gov. RetaPath is not affiliated with Eli Lilly or any study authors. For informational purposes only — not medical advice.